SUMMIT THERAPEUTICS
Summit Therapeutics is a clinical-stage drug discovery and development company. The company's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
SUMMIT THERAPEUTICS
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2003-01-01
Address:
Abingdon, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.summittxinc.com
Total Employee:
101+
Status:
Active
Contact:
+44 (0)1235 443 939
Email Addresses:
[email protected]
Total Funding:
1.06 B USD
Technology used in webpage:
DMARC Slack
Similar Organizations
Ability Pharmaceuticals
Ability Pharmaceuticals is a drug discovery and development company.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Cerebral Therapeutics
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Redx Pharma
Redx Pharma is a drug discovery and development company.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Synaptic Medical
Synaptic Medical is a medical device company.
Xeltis
Xeltis is a clinical-stage medtech company with the world’s most advanced polymer-based platform of restorative cardiovascular devices.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-12-23 | Discuva | Discuva acquired by Summit Therapeutics | N/A |
| 2007-03-30 | DanioLabs | DanioLabs acquired by Summit Therapeutics | 30 M USD |
Investors List
Robert W. Duggan
Robert W. Duggan investment in Post-IPO Equity - Summit Therapeutics
Maky Zanganeh
Maky Zanganeh investment in Post-IPO Equity - Summit Therapeutics
CARB-X
CARB-X investment in Grant - Summit Therapeutics
Maky Zanganeh
Maky Zanganeh investment in Post-IPO Equity - Summit Therapeutics
Robert W. Duggan
Robert W. Duggan investment in Post-IPO Equity - Summit Therapeutics
Eurofarma
Eurofarma investment in Post-IPO Equity - Summit Therapeutics
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Post-IPO Equity - Summit Therapeutics
Robert W. Duggan
Robert W. Duggan investment in Post-IPO Equity - Summit Therapeutics
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Post-IPO Equity - Summit Therapeutics
CARB-X
CARB-X investment in Grant - Summit Therapeutics
Key Employee Changes
Official Site Inspections
http://www.summittxinc.com Semrush global rank: 6.09 M Semrush visits lastest month: 1.13 K
- Host name: linux9.neonstone.com
- IP address: 141.94.254.149
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Summit Therapeutics"
Company - Summit Therapeutics
Summit Mission Statement To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory …See details»
ABOUT SUMMIT THERAPEUTICS,INC
Europe, and Japan – an important step towards Akeso’s strategic intention of becoming a global biopharma organization. IVONESCIMAB. Ivonescimab is the most advanced PD-1/VEGF …See details»
Committed to being a leader in microbiome-preserving, precision ...
To build a viable, long -lasting health care organization that assumes full responsibility for designing, developing, trial enrollment, regulatory approval, and commercializing ...See details»
Summit Therapeutics, Inc. | LinkedIn
Summit Therapeutics, Inc. | 20,836 followers on LinkedIn. Summit Therapeutics’ mission is to resolve serious, unmet medical needs for the betterment of overall human health. | Summit …See details»
Summit Therapeutics CEO and Key Executive Team | Craft.co
Summit Therapeutics's Executive Chairman and Chief Executive Officer is Robert W. Duggan. Other executives include Maky Zanganeh, Co-Chief Executive Officer, President & Director; …See details»
Summit Therapeutics - Crunchbase Company Profile & Funding
Summit Therapeutics is a clinical-stage drug discovery and development company. The company's new mechanism antibiotics are designed to become the new standards of care for …See details»
Summit Therapeutics Announces Preclinical Candidate and …
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in …See details»
CARB-X is funding Summit Therapeutics to develop a new …
May 18, 2021 First-in-class antibiotic to treat serious infections caused by pathogens identified as a ‘critical priority’ by the World Health Organization (WHO) and as an ‘urgent threat’ by the …See details»
Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO
Bob Duggan Remains Chairman of the Board of Directors and CEOMenlo Park, California, July 26, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) announces …See details»
Summit Therapeutics Appoints Ankur Dhingra as Chief Financial …
Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Ankur Dhingra has been appointed as Chief Financial Officer, …See details»
Summit Therapeutics Provides Update on Ridinilazole
Jul 14, 2022 To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission …See details»
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 ...
Dec 6, 2022 The presentation will be available afterwards through Summit’s website at https://www.summittxinc.com. Summit Therapeutics’ Mission Statement To build a viable, long …See details»
Summit Therapeutics Announces Preclinical Candidate and
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738...See details»
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
Rescheduled to June 16, 2022, at 1:00pm Eastern TimeMenlo Park, CA, June 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and …See details»
Summit Therapeutics Partners with Akeso Inc. in Deal for Up
Dec 6, 2022 To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission …See details»
Summit Therapeutics Presents Further Breakthrough Insights
Sep 30, 2021 Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying an …See details»
Summit Therapeutics Inc. (SMMT.MX) - Yahoo Finance Canada
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal …See details»
Summit Therapeutics Inc Reports Financial Results and Operational ...
Mar 17, 2022 Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutics fieldCambridge, MA, March 17, 2022 (GLOBE NEWSWIRE) -- …See details»
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 ...
$500 Million Upfront Payment to Activate the Partnership for IvonescimabMenlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Summit …See details»